Cepeda Javier, Tranche-Iparraguirre Salvador, Marín-Iranzo Rafael, Fernández-Rodríguez Eloy, Riesgo-García Alba, García-Casas Juan, Hevia-Rodríguez Eduardo
Servicio de Análisis Clínicos. Hospital Santos Reyes. Sanidad de Castilla y León (SACYL). Aranda de Duero. Burgos. España.
Rev Esp Cardiol. 2010 Apr;63(4):415-22.
Cystatin C has been proposed as a novel marker of renal function and as a predictor of cardiovascular risk in the elderly. The aim of this study was to determine the prevalence of an elevated cystatin C level in the general population and its relationship with cardiovascular risk factors and disease.
This descriptive epidemiologic cross-sectional study involved a simple randomized sample of individuals aged >49 years from the general population, and was based on personal health records. From the final selection of 415 individuals, 359 underwent cystatin C measurement using a immunonephelometric assay. The cut-point used was that recommended for the method in adults.
Of the 359 individuals (mean+/-standard deviation age, 64+/-10 years, 63.5% female) studied, 17.3% (95% confidence interval [CI] 13.4%-21.2%) had an elevated cystatin C level. The mean level was 0.81+/-0.21 mg/L, and increased with age. Elevation of the cystatin C level was associated with: older age (P< .0001); high measures of systolic blood pressure (P< .0001), hemoglobin A1c (P=.031), triglycerides (P=.019), homocysteine (P< .0001), C-reactive protein (P=.015), fibrinogen (P=.006) and microalbuminuria (P=.001); and a low high-density lipoprotein cholesterol level (P=.021) and estimated glomerular filtration rate (P< .0001). Associated cardiovascular diseases included coronary heart disease (P=.013) and heart failure (P=.038). The main factors independently associated with an elevated cystatin C level were diabetes (odds ratio [OR]=5.37), male sex (OR=4.91) and decreased glomerular filtration (OR=0.83).
The prevalence of an elevated cystatin C level in the general population was found to be high and was associated with the presence of classical cardiovascular risk factors such as diabetes, hypertension and chronic renal disease, along with higher levels of C-reactive protein, homocysteine and fibrinogen.
胱抑素C已被提议作为肾功能的一种新型标志物以及老年人心血管疾病风险的预测指标。本研究的目的是确定普通人群中胱抑素C水平升高的患病率及其与心血管疾病风险因素和疾病的关系。
这项描述性流行病学横断面研究纳入了来自普通人群的49岁以上个体的简单随机样本,并基于个人健康记录。在最终选定的415名个体中,359人采用免疫比浊法进行了胱抑素C检测。所采用的切点是该方法针对成年人推荐的切点。
在研究的359名个体(平均年龄±标准差为64±10岁,女性占63.5%)中,17.3%(95%置信区间[CI]为13.4%-21.2%)的胱抑素C水平升高。平均水平为0.81±0.21mg/L,并随年龄增长而升高。胱抑素C水平升高与以下因素相关:年龄较大(P<0.0001);收缩压升高(P<0.0001)、糖化血红蛋白(P=0.031)、甘油三酯(P=0.019)、同型半胱氨酸(P<0.0001)、C反应蛋白(P=0.015)、纤维蛋白原(P=0.006)和微量白蛋白尿(P=0.001);以及高密度脂蛋白胆固醇水平较低(P=0.021)和估计肾小球滤过率较低(P<0.0001)。相关的心血管疾病包括冠心病(P=0.013)和心力衰竭(P=0.038)。与胱抑素C水平升高独立相关的主要因素是糖尿病(比值比[OR]=5.37)、男性(OR=4.91)和肾小球滤过率降低(OR=0.83)。
普通人群中胱抑素C水平升高的患病率较高,且与糖尿病、高血压和慢性肾病等经典心血管疾病风险因素的存在以及C反应蛋白、同型半胱氨酸和纤维蛋白原水平升高相关。